From the Journals

Mild cortisol excess increases mortality in adrenal incidentaloma


 

Implications: Further testing, prospective studies needed

“The increase in mortality associated with cortisol DST values of 83 nmol/L or higher has implications,” the authors say.

“We suggest [medical] treatment of known cardiovascular risk factors in these patients and incorporation of our results in the decision about which patients to recommend for adrenalectomy.”

In contrast, ACS with lower cortisol (<83 nmol/L or 3 µg/dL) following DST “is not associated with clinically relevant increased mortality within 5 to 10 years,” they observe.

Dr. Kurra said she would perform further testing for any patient with an adrenal incidentaloma and a cortisol level 50-137 nmol/L (1.8-5 µg/dL) following DST: Specifically, a dehydroepiandrosterone sulfate (DHEAS) test.

“If DHEAS is low and the patient has metabolic complications, then I will work them up more, with adrenocorticotropin (ACTH) and 24-hour urine and go down that path of looking for the extent of overproduction of cortisol.”

She recommended an algorithm published in 2017 of an age- and sex-adjusted DHEAS ratio that provides a sensitive and specific screening test for subclinical hypercortisolism in patients with adrenal incidentalomas.

In further analyses by Dr. Kjellbom and colleagues into incidentaloma size, bilateralism, basal ACTH less than 2.0 pmol/L, or DHEAS less than 1.04 mmol/L, only DHEAS significantly predicted mortality.

“This should be studied further, specific to sex, age, and [post-DST]-cortisol strata,” Dr. Kjellbom and colleagues say.

In conclusion, Dr. Kurra said the new data “confirm something that people have postulated. But because it’s a retrospective review, we need prospective studies. It is an interesting finding that needs further study before we can change clinical practice.”

The study was funded by unrestricted grants from the Lisa and Johan Grönberg Foundation and the Gyllenstiernska Krapperup Foundation. Dr. Kjellbom and Dr. Kurra have reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Imaging alternative to AVS could boost detection of primary aldosteronism
MDedge Endocrinology
Success in achondroplasia spurs testing vosoritide in more growth disorders
MDedge Endocrinology
1 in 3 on levothyroxine take meds that interfere with thyroid tests
MDedge Endocrinology
Metyrapone for Cushing’s syndrome: Safe, effective in first test
MDedge Endocrinology
Combo thyroid hormones as good as levothyroxine for hypothyroidism
MDedge Endocrinology
COVID-19 can cause atypical thyroid inflammation
MDedge Endocrinology
In low-risk thyroid cancer, no advantage found for postsurgical iodine
MDedge Endocrinology
Cushing’s death rate ‘unacceptable,’ triple that of general population
MDedge Endocrinology
Acella recalls NP Thyroid lots found to have reduced potency
MDedge Endocrinology
Two treatments show early promise for hypothalamic obesity
MDedge Endocrinology